Sign in

NCT03957681CompletedPhase 3

A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

A Phase 3, Placebo-controlled, Double-blind Comparative Study of KHK4827 With an Open-label Extension Period in Subjects With Systemic Sclerosis Who Have Moderate to Severe Skin Thickening

Source: ClinicalTrials.gov · Last updated 11 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

To evaluate the efficacy and safety of KHK4827 in patients with systemic sclerosis who have moderate to severe skin thickening

Status (registry)
Completed
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
100 (actual)
First submitted
16 May 2019
Start date
23 May 2019
Primary completion date
16 Oct 2020
Lead sponsor
Kyowa Kirin Co., Ltd.
NCT number
NCT03957681

What you commit to

  • Study type: Interventional · Phase 3
  • Participants enrolled: 100
  • From 23 May 2019 to the primary completion date, 16 Oct 2020
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patient has a history or evidence of a psychiatric disorder, alcohol and/or substance abuse, or any other mental health disorder that, in the opinion of the investigators, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion

Lab values

  • Any of the following significant concomitant diseases:
    • Type 1 diabetes
    • Poorly controlled type 2 diabetes (HbA1c \> 8.5%)
    • Congestive heart failure (Class II to IV of the New York Heart Association Functional Classification)
    • Myocartial infarction, unstable angina, or stroke occurring within 12 months before the first dose of investigational product
    • Poorly controlled hypertension (systolic pressure \> 150 mm Hg or diastolic pressure \> 90 mg Hg at screening)
    • Severe chronic lung disease (%FVC \< 60% and %DLco \< 40%, calculated according to the Reference Values for Spirometry, Including Viral Capacity, in Japanese Adults Calcluated with the LMS Method and Compared with Previous Values \[Japanese Respiratory Society\])
    • Major chronic inflammatory diseases or connective tissue diseases other than scleroderma

Other

  • Patient has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating Scale (C-SSRS) at enrollment
  • Patient has severe depression based on a total score of ≥ 15 on the Patient Health Questionnaire-8 (PHQ-8) at enrollment

Who the study is looking for

  • Subject meets the criteria for diagnosis of the Diagnostic Criteria, Severity Classification, and Clinical Practice Guidelines for Systemic Sclerosis (Japanese Dermatological Association 2016) at the pre-examination
  • Subject presented the first symptoms of sclerosis other than Raynaud's phenomenon within 60 months before enrollment
  • Subject who has systemic sclerosis accompanied by moderate to severe skin thickening with an mRSS of 10 to \<30 at the pre-examination and who has progressing skin thickening

Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Fukushima Medical University Hospital
Coordinator of this site? Confirm its status
FukushimaJapanUnknown status
St. Marianna University School of Medecine Hospital
Coordinator of this site? Confirm its status
KawasakiJapanUnknown status
Chukyo Hospital
Coordinator of this site? Confirm its status
NagoyaJapanUnknown status
Osaka University Hospital
Coordinator of this site? Confirm its status
SuitaJapanUnknown status
The University of Tokyo Hospital
Coordinator of this site? Confirm its status
TokyoJapanUnknown status
The University of Fukui Hospital
Coordinator of this site? Confirm its status
Yoshida-gunJapanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.